Business Wire

Mercedes-Benz Joins The Climate Pledge and Delivers More Than 1,800 Electric Vehicles to Amazon’s Delivery Fleet in Europe

28.8.2020 10:01:00 EEST | Business Wire | Press release

Share

Today, Amazon (NASDAQ: AMZN) announced it is adding more than 1,800 electric vehicles from Mercedes-Benz Vans to its delivery fleet in Europe this year. Amazon and Mercedes-Benz share a commitment to reduce emissions from the transportation sector, and Mercedes-Benz also announced today it has joined The Climate Pledge, which calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Agreement goal of 2050.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005049/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Electric vehicle (Photo: Business Wire)

“We welcome the bold leadership demonstrated by Mercedes-Benz by signing up to The Climate Pledge and committing to ambitious action to address climate change. We need continued innovation and partnership from auto manufacturers like Mercedes-Benz to decarbonize the transportation sector and tackle the climate crisis,” said Jeff Bezos, Amazon founder and CEO. “Amazon is adding 1,800 electric delivery vehicles from Mercedes-Benz as part of our journey to build the most sustainable transportation fleet in the world, and we will be moving fast to get these vans on the road this year.”

“At Mercedes-Benz, we have set ourselves the ambitious target to make the transformation of mobility a success story. By joining ‘The Climate Pledge’ we are building on our goal to consistently pursue emission-free mobility and sustainable vehicle production,” said Ola Källenius, Chairman of the Board of Management of Daimler AG and Mercedes-Benz AG. “We stand with Amazon, Global Optimism and the other signatories of The Climate Pledge, in a commitment to being net zero carbon by 2040 – ten years ahead of The Paris Agreement. I am pleased that we will be able to gain even more momentum on our sustainability offensive with this step.”

As part of Mercedes-Benz’s commitment as the latest signatory of The Climate Pledge, the company is doubling down on its commitment to "Ambition2039," a roadmap to CO2-neutral mobility. The company is evaluating ways to remove carbon from its entire value chain, from development to the supplier network, from its own production to the electrification of products and beyond, as well as to ensuring renewable energies for the use phase of electric vehicles. With its goal to have a CO2-neutral fleet of new cars in less than 20 years, Mercedes-Benz is making an important contribution to slowing climate change. The company is already making good progress in this direction: By the end of this year, the vehicle portfolio will comprise five fully electric models and more than 20 plug-in hybrids. Signatories to The Climate Pledge also have the opportunity to share access to technologies, best practices and innovations in supply chain enhancements. They are also able to co-invest in new technologies and emerging solutions.

Amazon’s Delivery Service Partners will have access to the new fleet of zero-emission vehicles to make deliveries to customers in Europe this year, helping to save thousands of metric tons of carbon. The order is a milestone for Mercedes-Benz Vans, marking the largest order of electric vehicles for the manufacturer to date, and makes Amazon its largest sustainable transportation partner worldwide. More than 1,200 EVs in the order will be comprised of the newest electric commercial van available at Mercedes-Benz – the eSprinter, a larger model than the manufacturer’s first zero-emission vehicle, the eVito. The eSprinter includes state-of-the-art safety features including, electrical parking brake, active brake assist, reverse camera, blind spot assist, and more. The remaining 600 vehicles will be comprised of the manufacturer’s midsize electric van, the eVito, to give Delivery Service Partners operating in geographies that require a smaller-format vehicle access to a zero-emissions delivery option.

"I am delighted that we are further intensifying our long-standing partnership with Amazon and working together on the battery-electric future of transportation," said Marcus Breitschwerdt, Head of Mercedes-Benz Vans. “With the eVito and the eSprinter, we have electric vehicles in our portfolio, which are ideally suited for the requirements of the courier-, express- and parcel-service industry for goods delivery on the so-called ‘last mile’ in terms of their equipment and range. They show that local emission-free driving, convincing performance, comfort and low operating costs can be combined perfectly.”

“Amazon’s investment is a strong and concrete sign of its commitment and alignment to EU priorities,” said Fabio Massimo Castaldo, Vice President at the European Parliament. “Amazon continues to contribute to the achievement of the EU Green Deal goals, foster technological innovation and generate resilient and sustainable jobs in Europe. I hope that other corporations will follow Amazon’s example in the near future.”

Amazon is also committed to powering its growing electric fleet with clean energy. As part of The Climate Pledge, Amazon is investing in renewable energy as a critical step toward addressing our carbon footprint globally and has committed to run on 100% renewable energy by 2025. Globally, Amazon has 91 renewable energy projects that have the capacity to generate over 2,900 MW and deliver more than 7.5 million MWh of energy annually. These projects include 31 utility-scale wind and solar renewable energy projects and 60 solar rooftops on fulfillment centers and sort centers around the globe.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit www.amazon.com/about and follow @AmazonNews.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye